ArticleLab on a chip2015
A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs.
Article in Lab on a chip, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 139 citations in OpenAlex.
- Advances in engineering organ-on-a-chip models of angiogenesis.Theranostics · 2026Review
- Synergistic Combination of Additive One- and Two-Photon Polymerization Printing Methods to Fabricate 3D Microstructured Perfusable Angiogenesis-on-a-Chip Systems.Engineering in life sciences · 2026Article
- A review of organ-on-chip fabrication methods: From early developments to overcoming inert barriers.iScience · 2025Review
- Pericytes Promote More Vascularization than Stromal Cells via an Interleukin-6-Dependent Mechanism in Microfluidic Chips.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Antagonizing the S1P-S1P3 Axis as a Promising Anti-Angiogenic Strategy.Metabolites · 2025Article
- Rethinking Biomedical Titanium Alloy Design: A Review of Challenges from Biological and Manufacturing Perspectives.Advanced healthcare materials · 2025Review
- Magnetically Integrated Tumor-Vascular Interface System to Mimic Pro-angiogenic Endothelial Dysregulations for On-Chip Drug Testing.ACS applied materials & interfaces · 2024Article
- Matrix Resistance Toward Proteolytic Cleavage Controls Contractility-Dependent Migration Modes During Angiogenic Sprouting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Self-assembled and perfusable microvasculature-on-chip for modeling leukocyte trafficking.Lab on a chip · 2024Article
- Angiogenesis-on-a-chip coupled with single-cell RNA sequencing reveals spatially differential activations of autophagy along angiogenic sprouts.Nature communications · 2024Article
- Bio-inspired microfluidics: A review.Biomicrofluidics · 2023Review
- Modeling angiogenesis in the human brain in a tissue-engineered post-capillary venule.Angiogenesis · 2023Article
- Engineered Vasculature for Cancer Research and Regenerative Medicine.Micromachines · 2023Review
- Building Blood Vessel Chips with Enhanced Physiological Relevance.Advanced materials technologies · 2023Article
- Spatiotemporal dissection of tumor microenvironment via in situ sensing and monitoring in tumor-on-a-chip.Biosensors & bioelectronics · 2023Article
- Organ-on-a-chip meets artificial intelligence in drug evaluation.Theranostics · 2023Review
- Sound-based assembly of a microcapillary network in a saturn-like tumor model for drug testing.Materials today. Bio · 2022Article
- Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies.Cancers · 2022Review
- Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system.Journal of nanobiotechnology · 2022Review
- An Easy-to-Fabricate Microfluidic Shallow Trench Induced Three-Dimensional Cell Culturing and Imaging (STICI3D) Platform.ACS omega · 2022Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Anti-angiogenic therapy, which suppresses tumor growth by disrupting oxygen and nutrient supply from blood to the tumor, is now widely accepted as a treatment for cancer. To investigate the mechanisms of action of these anti-angiogenesis drugs, new three dimensional (3D) cell culture-based drug screening models are increasingly employed. However, there is no in vitro high-throughput screening (HTS) angiogenesis assay that can provide uniform culture conditions for the quantitative assessment of physiological responses to chemoattractant reagents under various concentrations of anti-angiogenesis drugs. Here we describe a method for screening and quantifying the vascular endothelial growth factor (VEGF)-induced chemotactic response on human umbilical vein endothelial cells (HUVECs) cultured with different concentrations of bortezomib, a selective 26S proteasome inhibitor. With this quantitative microfluidic angiogenesis screen (QMAS), we demonstrate that bortezomib-induced endothelial cell death is preceded by a series of morphological changes that develop over several days. We also explore the mechanisms by which bortezomib can inhibit angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.